<DOC>
	<DOCNO>NCT01894399</DOCNO>
	<brief_summary>Study Design - Open , escalate single-dose design . - 7 ascend dose cohort - In cohort , subject receive single dose HM61713 . - Main objective study evaluate pharmacokinetics HM61713 tablet .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetic HM61713 Healthy Male Subjects</brief_title>
	<detailed_description>Primary objective • To assess PK characteristic HM61713 metabolites healthy male volunteer Secondary objective - To assess safety tolerability HM61713 tablet healthy male subject . - To assess food effect PK characteristic HM61713 tablet healthy male subject . - To assess ethnic difference PK characteristic HM61713 ( Korean , Japanese , Caucasian ) - To investigate genotype drug metabolism.transport affect PK characteristic HM61713 - To investigate change endogenous metabolic marker administration HM61713</detailed_description>
	<criteria>Healthy male volunteer , age 20 45 Informed investigational nature study voluntarily agree participate study BMI ＞18.5kg/m2 ＜28kg/m2 subject Use prescription medication within 2 week prior Day 1 Use medication within 1 week prior Day 1 Has severe medical history hypersensitivity drug Participation another clinical study within 8 week day prior start study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HM61713</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy</keyword>
	<keyword>olmutinib</keyword>
</DOC>